Compartilhar
Informação da revista
Vol. 39. Núm. 12.
Páginas 685-686 (Dezembro 2020)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Vol. 39. Núm. 12.
Páginas 685-686 (Dezembro 2020)
Editorial comment
DOI: 10.1016/j.repc.2020.10.004
Open Access
What is the best treatment for patients with myocardial infarction with non-obstructive coronary artery disease?
Qual é o melhor tratamento para os doentes com enfarte do miocárdio com doença coronária não obstrutiva?
Visitas
...
Mariana Gonçalvesa, Hector M. Garcia-Garciab,
Autor para correspondência
hect2701@gmail.com

Corresponding author.
a Division of Interventional Cardiology of Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal
b Division of Interventional Cardiology of MedStar Cardiovascular Research Network at MedStar Washington Hospital Center, United States of America
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Texto Completo

The article “Dual anti-platelet therapy in myocardial infarction with non-obstructive coronary artery disease – insights from a nationwide registry”1 raises the issue of the paucity of guidelines for medical treatment in patients presenting with acute coronary syndrome with non-obstructive coronary disease and aims to outline which factors seem to influence a clinician's decision to prescribe dual antiplatelet therapy (DAPT) at discharge. In a population of more than 16 000 patients presenting type 1 myocardial infarction (MI), only 4.4% were categorized as myocardial infarction with non-obstructed coronary artery (MINOCA). Among these patients, more than a half were discharged under dual antiplatelet therapy. More often, DAPT treated patients were male and smokers, presented sinus heart rhythm and trivial coronary lesions on a coronary angiography.

To the best of our knowledge, this is the first report to date analyzing real-world data about out-of-hospital management of MINOCA patients. It is a multicenter nationwide registry and one of the largest published MINOCA cohorts. However, it has some limitations as it is a single country registry. This underlies its limited external validity and also, there was limited or no data verification (or at least it is not disclosed in the report). Furthermore, no information was provided about the non-invasive diagnostic investigation after the invasive coronary angiography nor about the work up on which the final diagnosis of MINOCA was established. The data provided are therefore insufficient to clarify whether DAPT prescription was appropriate.

Indeed, the most surprising finding of this report is the high percentage (55%) of patients being discharged under DAPT. The current trends in medical treatment of coronary artery disease patients is to treat them for the shortest possible period (one to three months) with DAPT and to reduce it thereafter to monotherapy.2,3 This is particularly relevant in patients with high bleeding risk who may only need a potent P2Y12 inhibitor to prevent the excess when it is combined with aspirin.

Another important factor which compromises patient outcomes is the under recognition of the actual diagnosis. It may be harmful assuming non-obstructive disease excludes a plaque rupture-associated event with or without superimposed thrombus, which may or may not be apparent on angiography. Further, despite plaque rupture being responsible for two thirds of all coronary events,4 care should be taken not to dismiss plaque erosion that can be treated solely with antiplatelet therapy and anticoagulation, avoiding unnecessary stenting of the lesion.

Cardiac magnetic resonance (CMR) has gained a main role in this setting. Due to its safety, lower inter-observer variability, quantitative accuracy, and ability to characterize the myocardium, it has become a key diagnostic tool in the assessment of patients presenting with MINOCA.5 A meta-analysis gathering 46 publications,6 revealed the presence of a typical MI in CMR imaging in 24% of patients, with myocarditis occurring in 33%. This is a warning against the indiscriminate use of DAPT in this MINOCA population. Thus, CMR results may be required before discharge to inform decisions on DAPT treatment.

However, CMR does not identify the underlying cause (plaque disruption or erosion, embolism, dissection or vasospasm), which can be readily obtained with intracoronary imaging. Two independent studies using optical coherence tomography and intravascular ultrasound (IVUS) identified plaque rupture or ulceration in 40%7 and 24%8 of patients with MINOCA respectively, and 25% of those with plaque disruption identified in IVUS presented a normal CMR. These findings pose the question of whether invasive and non-invasive imaging should both be required in all MINOCA patients, as none of the imaging methods individually provide all the information needed to make the best clinical decision with regards to medical treatment.

The under recognition of the underlying cause of MINOCA may delay prognosis-modifying interventions, undermine or misguide lifestyle advice (restrictions or promotion of exercise, accordingly) and lead to a false sense of reassurance for both patients and clinicians. To conclude, efforts should be made to follow recommendations,5 clarify the diagnosis, treat and follow-up these patients and avoid unnecessary medication.

As stated by Poku and Noble (2016), “a more efficient management strategy may solely rely on an individualized approach in order to improve outcomes.”9

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
F.M. Sá, R. Carvalho, L. Santos.
Dual anti-platelet therapy in myocardial infarction with non-obstructive coronary artery disease – insights from a nationwide registry.
[2]
R. Mehran, U. Baber, S.K. Sharma, et al.
Ticagrelor with or without aspirin in high-risk patients after PCI.
N Engl J Med, 381 (2019), pp. 2032-2042
[3]
P. Vranckx, M. Valgimigli, P. Jüni, et al.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la.
Lancet, 392 (2018), pp. 940-949
[4]
S.S. Kanwar, G.W. Stone, M. Singh, et al.
Acute coronary syndromes without coronary plaque rupture.
Nat Rev Cardiol, 13 (2016), pp. 257-265
[5]
S. Agewall, J.F. Beltrame, H.R. Reynolds, et al.
ESC working group position paper on myocardial infarction with non-obstructive coronary arteries.
Eur Heart J, 38 (2017), pp. 143-153
[6]
S. Pasupathy, T. Air, R.P. Dreyer, et al.
Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.
Circulation, 131 (2015), pp. 861-870
[7]
H. Ouldzein, M. Elbaz, J. Roncalli, et al.
Plaque rupture and morphological characteristics of the culprit lesion in acute coronary syndromes without significant angiographic lesion: analysis by intravascular ultrasound.
Ann Cardiol Angeiol (Paris), 61 (2012), pp. 20-26
[8]
H.R. Reynolds, M.B. Srichai, S.N. Iqbal, et al.
Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease.
Circulation, 124 (2011), pp. 1414-1425
[9]
N. Poku, S. Noble.
Myocardial infarction with non obstructive coronary arteries (MINOCA): a whole new ball game.
Expert Rev Cardiovasc Ther, 15 (2017), pp. 7-14
Idiomas
Revista Portuguesa de Cardiologia

Receba a nossa Newsletter

Opções de artigo
Ferramentas
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico revista@spc.pt. Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.